Study on the immune status of blood donors in Yangzhou after SARS-COV-2 vaccinating
10.13303/j.cjbt.issn.1004-549x.2022.05.014
- VernacularTitle:扬州地区无偿献血人群新型冠状病毒疫苗接种免疫状况调查
- Author:
Enyong FAN
1
;
Haiying SUN
1
;
Minghua GUO
1
;
Shouguang XU
1
;
Chaofan DAI
1
Author Information
1. Yangzhou Blood Center, Yangzhou 225007, China
- Publication Type:Journal Article
- Keywords:
SARS-COV-2 vaccine;
voluntary blood donation;
enzyme-linked immunosorbent assay;
IgM antibody;
IgG antibody
- From:
Chinese Journal of Blood Transfusion
2022;35(5):537-541
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the immune status of blood donors in Yangzhou area after SARS-COV-2 vaccinating. 【Methods】 Among 112 voluntary blood donors from August 29 to September 22, 2021, 111 were vaccinated with SARS-COV-2 vaccine.IgM antibody(by enzyme-linked immunocapture method), IgG antibody(by indirect method of combined immunoassay)and IgG antibody titer were detected. 【Results】 A total of 99.11% (111/112 ) voluntary blood donors were vaccinated, two-shot(n=103), one-shot(n=1) and three-shot (n=7) accounting for 91.96%, 0.89% and 6.25%, respectively.Eighty-eight (78.57%) were positive for IgG antibodies, and 14 (12.5%) were positive for IgM antibodies.No statistically significant difference was found in IgG and IgM positive yielding between males and females (P>0.05). The proportion (0.89%, 1/112) of positive IgM in blood donors with blood type A was significantly lower than that of other blood types (P<0.01). The IgG antibody titer of blood donors maintained rather high level within 6 months after vaccinating.47.66% of the donors presented antibody titer more than 160, and 5.60% had IgM antibody been detected within 1 month after vaccinating. 【Conclusion】 At present, the SARS-COV-2 vaccination effect in China is generally good.Since IgG antibodies cannot be detected after 6 months, it is suggested to perform IgG antibody testing for donors who have completed the second dose for more than 6 months.For those IgG antibody negative, booster shots should be conducted.For donors with high IgG antibody titer, their plasma may be considered to replace with COVID-19 convalescent plasma for the treatment of patients with rapid disease progression, or severe/critically ill patients diagnosed with COVID-19, so as to avoid the risk of COVID-19 re-spreading during convalescent plasma collection in blood centers. For blood donors with positive IgM antibodies, it is recommended to follow up the NAT results to minimize the risk of transmission.
